Evidence map›Paper›PMID 33980706›Full record

ArticleNeurology2021

Intrathecal Production of MOG-IgG: Highlighting the Need for CSF Testing in Clinical Practice.

Yael Hacohen, Wesley Kerr, Patrick Waters

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Neurology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Induction of immune tolerance in NMOSD and MOGAD.Therapeutic advances in neurological disorders · 2025
    Review
  2. Article
  3. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Yael HacohenFrom the Queen Square MS Centre (Y.H.), UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London; Department of Neurology (Y.H.), Great Ormond Street Hospital for Children, London, UK; Department of Neurology (W.K.), David Geffen School of Medicine at UCLA, Los Angeles, CA; and Nuffield Department of Clinical Neurosciences (P.W.), John Radcliffe Hospital, Oxford, UK. y.hacohen@ucl.ac.uk.
Wesley KerrFrom the Queen Square MS Centre (Y.H.), UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London; Department of Neurology (Y.H.), Great Ormond Street Hospital for Children, London, UK; Department of Neurology (W.K.), David Geffen School of Medicine at UCLA, Los Angeles, CA; and Nuffield Department of Clinical Neurosciences (P.W.), John Radcliffe Hospital, Oxford, UK.ORCID 0000-0002-5546-5951
Patrick WatersFrom the Queen Square MS Centre (Y.H.), UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London; Department of Neurology (Y.H.), Great Ormond Street Hospital for Children, London, UK; Department of Neurology (W.K.), David Geffen School of Medicine at UCLA, Los Angeles, CA; and Nuffield Department of Clinical Neurosciences (P.W.), John Radcliffe Hospital, Oxford, UK.ORCID 0000-0003-4142-2667

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple SclerosisHumansImmunoglobulin GMyelin-Oligodendrocyte GlycoproteinImmunoglobulin GMyelin-Oligodendrocyte Glycoprotein

Identifiers

PMID33980706

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.